Samil Pharm (000520) - Net Assets

Latest as of June 2025: ₩149.26 Billion KRW ≈ $101.15 Million USD

Based on the latest financial reports, Samil Pharm (000520) has net assets worth ₩149.26 Billion KRW (≈ $101.15 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩375.58 Billion ≈ $254.52 Million USD) and total liabilities (₩226.31 Billion ≈ $153.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Samil Pharm (000520) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩149.26 Billion
% of Total Assets	39.74%
Annual Growth Rate	7.77%
5-Year Change	177.14%
10-Year Change	223.7%
Growth Volatility	26.67

Samil Pharm - Net Assets Trend (2011–2024)

This chart illustrates how Samil Pharm's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Samil Pharm (000520) total market value.

Annual Net Assets for Samil Pharm (2011–2024)

The table below shows the annual net assets of Samil Pharm from 2011 to 2024. Also explore Samil Pharm annual equity growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	₩176.12 Billion ≈ $119.36 Million	+37.78%
2023-12-31	₩127.83 Billion ≈ $86.63 Million	+1.60%
2022-12-31	₩125.82 Billion ≈ $85.27 Million	+91.37%
2021-12-31	₩65.75 Billion ≈ $44.56 Million	+3.45%
2020-12-31	₩63.55 Billion ≈ $43.07 Million	+2.05%
2019-12-31	₩62.27 Billion ≈ $42.20 Million	+11.04%
2018-12-31	₩56.08 Billion ≈ $38.01 Million	+9.61%
2017-12-31	₩51.17 Billion ≈ $34.68 Million	-3.22%
2016-12-31	₩52.87 Billion ≈ $35.83 Million	-2.83%
2015-12-31	₩54.41 Billion ≈ $36.87 Million	-1.81%
2014-12-31	₩55.42 Billion ≈ $37.55 Million	-20.87%
2013-12-31	₩70.03 Billion ≈ $47.46 Million	+11.38%
2012-12-31	₩62.87 Billion ≈ $42.61 Million	-5.60%
2011-12-31	₩66.60 Billion ≈ $45.14 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Samil Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1993656137000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩19.94 Billion	11.32%
Other Components	₩156.19 Billion	88.68%
Total Equity	₩176.12 Billion	100.00%

Samil Pharm Competitors by Market Cap

The table below lists competitors of Samil Pharm ranked by their market capitalization.

Company	Market Cap
Corner Growth Acquisition Corp NASDAQ:COOL	$113.94 Million
Procaps Group SA NASDAQ:PROC	$113.95 Million
We&Win Diversification Co Ltd TWO:4113	$113.97 Million
Abra Information Technologies TA:ABRA	$114.04 Million
Boldt S.A BA:BOLT	$113.78 Million
Black Diamond Therapeutics Inc NASDAQ:BDTX	$113.76 Million
Sunspring Metal Corp TW:2062	$113.73 Million
Hiap Teck Venture Bhd KLSE:5072	$113.73 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Samil Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 127,827,371,780 to 176,123,873,000, a change of 48,296,501,220 (37.8%).
Net loss of 5,628,801,980 reduced equity.
Other factors increased equity by 53,925,303,200.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-5.63 Billion	-3.2%
Other Changes	₩53.93 Billion	+30.62%
Total Change	₩-	37.78%

Book Value vs Market Value Analysis

This analysis compares Samil Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.95x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.63x to 0.95x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩4844.18	₩7910.00	x
2018-12-31	₩4594.32	₩7910.00	x
2019-12-31	₩5082.66	₩7910.00	x
2020-12-31	₩5077.90	₩7910.00	x
2021-12-31	₩5201.33	₩7910.00	x
2022-12-31	₩9021.50	₩7910.00	x
2023-12-31	₩8838.55	₩7910.00	x
2024-12-31	₩8296.13	₩7910.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Samil Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -3.20%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -2.56%
• Asset Turnover: 0.56x
• Equity Multiplier: 2.24x
Recent ROE (-3.20%) is below the historical average (-2.54%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	11.32%	8.89%	0.77x	1.65x	₩927.34 Million
2014	-20.19%	-13.09%	0.79x	1.95x	₩-16.73 Billion
2015	1.08%	0.67%	0.89x	1.83x	₩-4.85 Billion
2016	1.68%	0.92%	0.96x	1.91x	₩-4.40 Billion
2017	-2.48%	-1.38%	0.68x	2.65x	₩-6.38 Billion
2018	-15.27%	-9.05%	0.64x	2.64x	₩-14.17 Billion
2019	1.26%	0.65%	0.66x	2.95x	₩-5.44 Billion
2020	2.11%	1.09%	0.64x	3.02x	₩-5.01 Billion
2021	-8.13%	-3.98%	0.59x	3.44x	₩-11.92 Billion
2022	-0.02%	-0.02%	0.50x	2.84x	₩-12.61 Billion
2023	1.30%	0.85%	0.53x	2.90x	₩-11.12 Billion
2024	-3.20%	-2.56%	0.56x	2.24x	₩-23.24 Billion

Industry Comparison

This section compares Samil Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $443,409,687,130
Average return on equity (ROE) among peers: -2.89%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Samil Pharm (000520)	₩149.26 Billion	11.32%	1.52x	$113.80 Million
Dongwha Pharm.Co.Ltd (000020)	$401.68 Billion	1.39%	0.54x	$93.92 Million
Yuhan Corp. (000100)	$519.03 Billion	9.81%	0.47x	$3.75 Billion
Yuhan Corp Preferred (000105)	$2.01 Trillion	4.74%	0.23x	$45.29 Million
Yuyu Pharma (000220)	$120.36 Billion	-5.97%	0.65x	$40.96 Million
Yuyu Pharma Inc (000225)	$140.54 Billion	5.80%	0.47x	$14.45 Million
Yuyu Pharma Inc (000227)	$86.87 Billion	4.63%	0.56x	$30.54 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$46.46 Million
Donga Socio Holdings (000640)	$319.55 Billion	0.00%	1.29x	$405.77 Million
Jw Pharmac (001060)	$225.76 Billion	14.13%	1.78x	$406.49 Million

About Samil Pharm

KO:000520 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$113.80 Million

₩167.93 Billion KRW

Market Cap Rank

#18812 Global

#881 in Korea

Share Price

₩7910.00

Change (1 day)

-3.77%

52-Week Range

₩5830.00 - ₩12310.00

All Time High

₩23603.13